BUHLMANN News

BUHLMANN Debriefing- EuroMedLab 2019

BÜHLMANN Educational Workshop at EuroMedLab 2019 The BÜHLMANN Educational Workshop at EuroMedLab 2019 about optimizing your lab workflow for fecal calprotectin testing was a great success. Fecal calprotectin is a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool and has been shown to be extremely useful as an aid for
Continue Reading

Visit BUHLMANN at Meeting of the Minds 2019

Meeting of the Minds 2019 BUHLMANN Diagnostics Corp Stop by our Booth! Nov 15-16, 2019 | Ritz Carlton Hotel | Toronto, ON Event Info: https://crohnsandcolitis.ca/meetingoftheminds Visit our booth to get an update on our IBDoc® Calprotectin Home Test: IBDoc®, the in-vitro diagnostic POC and home testing device to measure the inflammatory marker, fecal calprotectin Learn More Click & Contact Meeting of the Minds
Continue Reading

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Bodini, G. et al. Therapeutic Drug Monitoring in Crohn's Disease Patients, A Comparison Between Homogenous Mobility Shift Assay and Point of Care Method.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain.  P1750.  Read Citation BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health
Continue Reading

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster   “Use of IBDsmart and IBDoc® in
Continue Reading

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

BÜHLMANN IBDoc®: Orfanourdaki et al. The Real World Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease Under Maintenance Treatment with Adalimumab.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1074 Read Citation Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is Not Available for Sale in the US.
Continue Reading

Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of IBD from IBS

BÜHLMANN fCAL® ELISA Citation Berinstein, J. et al.  The Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of Inflammatory Bowel Disease from Irritable Bowel Syndrome: A Multi-Center Prospective Case-Control Study.  Crohn's & Colitis 360 (2019).  DOI: https://doi.org/10.1093/crocol/otz037. [Accepted Manuscript] Highlight from this Publication “The BÜHLMANN fCAL ELISA demonstrates excellent discriminating between IBD and IBS.”
Continue Reading

CALEX Cap Promotion

CALEX® Cap CALEX® Cap is an FDA 510(k) cleared fecal extraction device for use with BÜHLMANN fCAL® turbo that provides excellent correlation to the traditional manual weighing method and offers efficient, convenient and hygienic extraction of stool samples. Its unique design makes CALEX® Cap compatible with Total Laboratory Automation (TLA) solutions, minimizing the complexity of
Continue Reading

IBDoc Learning with Video Tutorials

New IBDoc® Tutorials (available on: ibdoc.net) IBDoc® Portal Tutorial videos offer: Quick and easy training for the sites to learn the important portal functionalities Updated healthcare professional and patient training Who Are the Videos for? Clinical Administrators Clinical Users View these six new IBDoc® Portal Tutorial Videos. They are geared toward helping Healthcare Professionals that
Continue Reading

BÜHLMANN fCAL® turbo Success Story- Freeman Hospital, Newcastle

The Benefits of Switching to BÜHLMANN Assay for Calprotectin Testing Dr. Elodie Hanon, Prinicpal Clinial Scientist at the Freeman Hospital, Newcastle, UK (Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories.) Highlight from this Perspective Article "We went live with the fCAL turbo in March 2018, and there really have been no issues. The turn-around time
Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for CALEX®Cap Calprotectin Extraction Device

BÜHLMANN CALEX® Cap, a single use tube intended for the preparation of human stool samples to be used with the BÜHLMANN fCAL® turbo, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, 2019: BÜHLMANN Laboratories AG, is proud to announce it received United
Continue Reading